Perspective Therapeutics Inc. (CATX)
NYSE: CATXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 2.48 +0.81%
CATX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $280.81M
- EPS (TTM)
- -$1.33
- Dividend yield
- None
- 52-week range
- 1.96 – 6.16
- Day range
- 2.32 – 2.51
- Volume / Avg
- 1.29M / 1.68M
- Beta
- —
- Shares outstanding
- 114.15M
52-week range
CATX stock today
On Oct 7, CATX ended the session at $2.46, adding $0.10 (4.24%), versus the S&P 500's 0.22% decline. At this level, CATX sits near the bottom of its 52-week range of $1.96 to $6.16: 60.1% below the high, set on Jan 29, 2026 and 25.5% above the low. CATX is down 10.5% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 29.1%.
Perspective Therapeutics has posted a net loss over the last twelve months (EPS of -$1.33), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Perspective Therapeutics
Company profilePerspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Johan M. Spoor
- Headquarters
- Seattle, WA
- Employees
- 163
- Website
- perspectivetherapeutics.com
Analyst forecast
ForecastConsensus (16 analysts)
strong_buy
Avg. price target
$12.29+399.59%
- Strong buy 2
- Buy 13
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
CATX news
All CATX newsPerspective Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| FULCFulcrum Therapeutics Inc. | 3.67 | -0.54% | $280.01M | vs CATX |
| RCKTRocket Pharmaceuticals Inc. | 2.54 | +2.22% | $278.28M | vs CATX |
| LRMRLarimar Therapeutics Inc. | 2.75 | -1.08% | $285.68M | vs CATX |
| BBOTBridgeBio Oncology Therapeutics Inc. | 3.44 | -1.71% | $275.80M | vs CATX |
| VNDAVanda Pharmaceuticals Inc. | 4.56 | +0.89% | $275.71M | vs CATX |
| BIOABioAge Labs Inc. | 6.26 | -0.48% | $287.31M | vs CATX |
| ABEOAbeona Therapeutics Inc. | 5.08 | +1.40% | $290.49M | vs CATX |
| BCYCBicycle Therapeutics plc ADR | 3.73 | -1.58% | $261.07M | vs CATX |
Indexes, lists and sector
Perspective Therapeutics stock FAQ
What is Perspective Therapeutics's stock price today?
CATX last traded at $2.46 as of Oct 7, 4:00 PM EDT, up 4.24% on the day. Prices are delayed at least 15 minutes.
Does Perspective Therapeutics pay a dividend?
No. Perspective Therapeutics does not currently pay a regular cash dividend.
Who is Perspective Therapeutics's CEO?
Mr. Johan M. Spoor is the chief executive officer of Perspective Therapeutics Inc., which has about 163 employees.
Has CATX ever split its stock?
Yes. The most recent CATX stock split was a 1-for-10 split on Jun 17, 2024.
What is the CATX 52-week high?
The 52-week high for CATX is $6.16 and the 52-week low is $1.96. The stock is currently 60.1% below its high.